

British HIV Association
BHIVA

FINAL PROGRAMME

BHIVA Autumn Conference

12–13 November 2015

QEI Centre
London

including

CHIVA Parallel Sessions

Friday 13 November 2015



12 CPD Credits
Reference No:
98788

www.bhiva.org



inner strength

THE ONLY SINGLE-PILL REGIMEN
BUILT WITH DOLUTEGRAVIR

The treatment effects seen with dolutegravir were consistent across subgroups regardless of sex, age, race, baseline viral load, background regimen and CD4⁺ T-cell count. The components of TRIUMEQ[®] were generally better tolerated vs Atripla[®] up to 144 weeks.¹⁻³

Before initiating treatment with abacavir-containing products, HLA-B*5701 status must always be documented. Abacavir should not be used in patients known to carry the HLA-B*5701 allele due to the risk of hypersensitivity reaction.

*In studies supporting TRIUMEQ, DTG 50 mg + ABC 600 mg/3TC 300 mg were used. Bioequivalence has been demonstrated.¹

Visit www.dolutegravir.com for more information.

Prescribing Information

Triumeq[®] ▼ dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg tablets

See Summary of Product Characteristics before prescribing.

Indication: HIV in over 12 years and ≥ 40 kg. Screen for HLA-B*5701 prior to use. Do not use if HLA-B*5701 positive. **Dose:** one tablet once daily with or without food. **Elderly:** Limited data in 65+ yrs. **Creatinine clearance** <50 ml/min or moderate/severe hepatic impairment: Not recommended. **Contraindications:** Hypersensitivity to any ingredient. Co-administration with dofetilide. **Warnings/precautions:** Both abacavir and dolutegravir are associated with risk of hypersensitivity reactions (HSR). Do not initiate in HLA-B*5701+ or previous suspected abacavir HSR. Stop Triumeq without delay if HSR suspected. Never reintroduce any dolutegravir- or abacavir-containing product after suspected HSR. Risks of lactic acidosis, lipodystrophy, immune reactivation syndrome, osteonecrosis. Monitor LFTs in Hepatitis B/C co-infection. Inconclusive data on relationship between abacavir and MI; minimise all modifiable CV risk factors (e.g. smoking, hypertension, hyperlipidaemia). Not recommended if dolutegravir required b.d. (with efavirenz (without boosted PI), efavirenz, nevirapine, rifampicin, boosted tipranavir, carbamazepine, oxcarbazepine, phenytoin, phenobarbital and St John's Wort). Use with cladribine not recommended. Use with Mg/Al-containing antacids, calcium, multivitamins or iron requires dosage separation. Caution with metformin: monitor renal function and consider metformin dose adjustment. Caution with ribavirin. **Pregnancy/lactation:** Not recommended. Avoid breast-feeding. **Side effects:** See SPC for details. Headache, insomnia, sleep/dream disorders, GI disturbance, fatigue, hypersensitivity, anorexia, depression, dizziness, somnolence, lethargy, malaise, cough, nasal symptoms, rash, pruritus,

alopecia, arthralgia, muscle disorders, asthenia, fever, elevations of ALT, AST and CPK, blood dyscrasias, suicidal ideation or suicide attempt, rhabdomyolysis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis. **Basic NHS costs:** 30 tablets: £798.16 EU/1/14/940/001. MA holder: ViiV Healthcare UK Ltd, 980 Great West Road, Brentford, Middlesex TW8 9GS. Further information is available from Customer Contact Centre, GlaxoSmithKline UK Ltd, Stockley Park West, Uxbridge, Middlesex UB11 1BT.

POM

Triumeq is a registered trademark of the ViiV Healthcare Group of Companies

Date of approval: July 2015

Zinc code: UK/TRIM/0037/14(3)

Adverse events should be reported. For the UK, reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

Adverse events should be reported. For Ireland, adverse events should be reported directly to the HPRA: Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971, medsafety@hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

References: 1. TRIUMEQ Summary of Product Characteristics. June 2015. 2. Raffi F et al. *AIDS*. 2015; 29(2): 167-174. 3. Pappa K et al. Presented at: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 5-9, 2014; Washington, DC, USA.



TRIUMEQ is a registered trademark of the ViiV Healthcare group of companies.
Atripla is a registered trademark of Bristol-Myers Squibb & Gilead Sciences, LLC.
©2015 ViiV Healthcare group of companies All rights reserved.

UK/TRIM/0022/14(3) Date of preparation: August 2015

INTRODUCTION

CONTENTS

| | | | |
|---|-------|------------------------------|-------|
| Programme Summary..... | 4 | Sponsors and Exhibitors..... | 15 |
| Programme (BHIVA Autumn)..... | 5-9 | Conference Information..... | 16-17 |
| Programme (CHIVA Parallel)..... | 10-11 | Exhibition..... | 18 |
| Satellite Symposia and Sponsors' Workshops..... | 12-13 | Speaker Biographies..... | 19-23 |
| BHIVA Committees..... | 14 | | |

Dear Colleague

Welcome to the **BHIVA Autumn Conference** held at the prestigious QEl Centre in the heart of London.

I would like to thank Chloe Orkin (Chair of the Conferences Subcommittee), Melinda Tenant-Flowers (Conference Local Host) and all the members of the Conferences Subcommittee for their efforts in preparing an excellent programme for this conference. In addition, we are delighted once again, to hold parallel sessions on Friday in collaboration with the Children's HIV Association (CHIVA).

The conference sessions will cover a wide range of important topics relevant to HIV. Please refer to the programme pages for a full schedule of topics and timings.

The BHIVA Annual General Meeting will be held on Friday 13 November prior to lunch. I would encourage all BHIVA members to attend this meeting as it provides a forum to bring together the BHIVA membership and an opportunity to present any points they may have to the BHIVA Officers and members of the Executive Committee.

Finally, we would like to thank our sponsors for their continued support of the Association which assists greatly with covering some of the costs incurred in organising this conference.

We very much hope you enjoy the programme and find it relevant to both your educational and practical needs.

Dr David Asboe
Chair, British HIV Association



CONFERENCE VENUE

| BHIVA Autumn Conference | | QEl Centre, Broad Sanctuary, London SW1P 3EE |
|---|--|--|
| Registration | | Sanctuary Foyer, Ground Floor |
| Lecture Theatre (all BHIVA sessions)..... | | Fleming, Third Floor |
| Lunchtime Workshops | | Abbey, Moore and Westminster, Fourth Floor |
| Satellite Symposia..... | | Fleming, Third Floor |
| Exhibition | | Britten, Third Floor |
| Lunch and Refreshments | | Britten, Third Floor |
| Speakers' Presentation Preview Room | | East Room, Third Floor |
| Drinks Reception | | Britten, Third Floor |
| CHIVA Parallel Sessions | | QEl Centre, Broad Sanctuary, London SW1P 3EE |
| Lecture Theatre..... | | Westminster, Fourth Floor |

12 CPD Credits

Unique reference number 98788

PROGRAMME SUMMARY

THURSDAY 12 NOVEMBER 2015

BHIVA Autumn Conference

| | |
|-----------|--|
| 0815–1830 | Registration and exhibition open |
| 0855–0900 | Welcome Address |
| 0900–1000 | Bristol-Myers Squibb Satellite Symposium |
| 1000–1030 | BHIVA Foundation Lecture |
| 1030–1100 | Morning coffee |
| 1100–1200 | BHIVA Guidelines Session |
| 1200–1230 | BHIVA Audit Session |
| 1230–1400 | Lunch and Lunchtime Workshops |
| 1240–1325 | BHIVA Lunchtime Workshop 1 |
| 1255–1355 | Janssen Lunchtime Workshop |
| 1255–1355 | Pfizer Lunchtime Workshop |
| 1400–1500 | BHIVA Plenary Session 1 |
| 1500–1600 | BHIVA Plenary Session 2 |
| 1600–1630 | Afternoon tea |
| 1630–1730 | BHIVA Community Symposium |
| 1730–1830 | ViiV Healthcare UK Satellite Symposium |
| 1830–1930 | Drinks Reception |

FRIDAY 13 NOVEMBER 2015

BHIVA Autumn Conference

CHIVA Parallel Sessions

| | | |
|-----------|---|--------------------|
| 0810–1440 | Registration and exhibition open | |
| 0825–0855 | BHIVA Breakfast Workshop | |
| 0900–1000 | Gilead Sciences Satellite Symposium | Parallel Session 1 |
| 1000–1030 | Brian Gazzard Lectureship in HIV Medicine | |
| 1030–1040 | BHIVA Awards Ceremony | |
| 1040–1110 | Morning coffee | |
| 1110–1140 | CHIVA Plenary Lecture | |
| 1140–1310 | BHIVA Best Practice Management Session | Parallel Session 2 |
| 1310–1330 | BHIVA Annual General Meeting | |
| 1310–1440 | Lunch and Lunchtime Workshops | |
| 1335–1420 | BHIVA Lunchtime Workshop 2 | |
| 1335–1435 | Gilead Sciences Lunchtime Workshop | |
| 1335–1435 | ViiV Healthcare UK Lunchtime Workshop | |
| 1440–1540 | BHIVA Plenary Session 3 | Parallel Session 3 |
| 1540–1640 | BHIVA Interactive Clinical and Ethical Conundrums | |
| 1640–1645 | Close | |

AUTUMN CONFERENCE PROGRAMME

THURSDAY 12 NOVEMBER 2015



BHIVA AUTUMN CONFERENCE

◀ All sessions will be held in the Fleming, Third Floor, QEl Centre unless otherwise stated ▶

| | |
|-----------|---|
| 0815–1830 | Registration and exhibition open |
| 0855–0900 | <p>Welcome Address by the Chair of the British HIV Association</p> <p>Dr David Asboe <i>Chelsea and Westminster Hospital, London</i></p> |
| 0900–1000 | Bristol-Myers Squibb Pharmaceuticals Satellite Symposium (see page 12 for further details) |
| 1000–1030 | <p>BHIVA Foundation Lecture</p> <p>Chair: Dr David Asboe <i>Chelsea and Westminster Hospital, London</i></p> <p>HIV and ageing – A review of the evidence Professor Brian Gazzard <i>Chelsea and Westminster Hospital, London</i></p> |
| 1030–1100 | Morning coffee |
| 1100–1200 | <p>BHIVA Guidelines Session</p> <p>Chairs: Dr Chloe Orkin <i>Barts Health NHS Trust, London</i></p> <p>Dr Adrian Palfreeman <i>Leicester Royal Infirmary</i></p> <p>Treatment guidelines Dr Duncan Churchill <i>Royal Sussex County Hospital, Brighton</i></p> <p>Dr Laura Waters <i>Mortimer Market Centre, London</i></p> <p>Monitoring guidelines Professor Brian Angus <i>University of Oxford</i></p> |
| 1200–1230 | <p>BHIVA Audit Session</p> <p>Chair: Dr Hilary Curtis <i>BHIVA Audit Coordinator</i></p> <p>Monitoring audit – preliminary results Dr Aoife Molloy <i>Royal Free London NHS Foundation Trust</i></p> |
| 1230–1400 | Lunch and Lunchtime Workshops |

AUTUMN CONFERENCE PROGRAMME

THURSDAY 12 NOVEMBER 2015

1240–1325

BHIVA Lunchtime Workshop 1 (Westminster, Fourth Floor)

Lunch packs will be provided (see page 16 for further details)

Clinico-pathological case presentations

Chair: Professor Sebastian Lucas

St Thomas' Hospital, London

An unexplained eosinophilia

Dr Lakshmi Jain

Mortimer Market Centre, London

Spot the diagnosis: bad bowels and HIV

Dr Jason Biswas

Northwick Park Hospital, London

Opportunistic infection or malignancy?

Dr Sarah Cavilla

Royal Sussex County Hospital, Brighton

1255–1355

Janssen Lunchtime Workshop (Abbey, Fourth Floor) (see page 12 for further details)

1255–1355

Pfizer Lunchtime Workshop (Moore, Fourth Floor) (see page 12 for further details)

1400–1500

BHIVA Plenary Session 1

Chairs: Professor Lucy Dorrell

University of Oxford

Professor Clifford Leen

Western General Hospital, Edinburgh

HIV prevention – what is happening in the UK and what is working – testing strategies

Dr Anthony Nardone

Public Health England

Dr Michael Rayment

Chelsea and Westminster Hospital, London

Implementing PrEP within a sexual health clinic

Mr Robbie Currie

Bexley Care Trust, Kent

Dr Mags Portman

Mortimer Market Centre, London

1500–1600

BHIVA Plenary Session 2

Chairs: Professor Mark Bower

Chelsea and Westminster Hospital, London

Professor Caroline Sabin

University College London

START Study

Professor Abdel Babiker

MRC Clinical Trials Unit at UCL, London

Stigma Index UK Study

Dr Valerie Delpech

Public Health England

Mr Alastair Hudson

Family Planning Association (FPA)

1600–1630

Afternoon tea

AUTUMN CONFERENCE PROGRAMME

THURSDAY 12 NOVEMBER 2015

1630–1730

BHIVA Community Symposium

The importance of peer support in HIV care

Chairs: Mr Garry Brough

UK Community Advisory Board (UK-CAB)

Dr Melinda Tenant-Flowers

King's College Hospital, London

Miss Laura K

Positively UK

Mr Marc Thompson

Positively UK

Mr Alex Sparrowhawk

Terrence Higgins Trust

Dr Ian Williams

University College London Medical School

1730–1830

ViiV Healthcare UK Satellite Symposium (see page 12 for further details)

1830–1930

Drinks Reception



EUROPEAN HIV HEPATITIS CO-INFECTION (EHHC) CONFERENCE

10–11 December 2015 • QEll Centre • LONDON

KEY CONFERENCE TOPICS AND SPEAKERS

State of the art in hepatitis C treatment

Graham Foster, Queen Mary University of London, UK

Data from real-life cohorts

Should we be doing baseline resistance testing?

Jean-Michel Pawlotsky, Hôpital Henri, Mondor, Créteil, France

Hepatitis C treatment failure: what next?

Ashley Brown, Imperial College Healthcare NHS Trust, London

Pharmacoeconomics of hepatitis C treatment

Andrew Hill, University of Liverpool, UK

Clinical case presentations session

Hepatitis B: new treatments, new targets and possible cure

Fabien Zoulim, Hospices Civils de Lyon, France

What happens to the liver after cure?

Lawrence Serfaty, Hôpital Saint-Antoine, Paris, France

Hepatitis E: epidemiology, transmission and treatment

Antonio Rivero-Juárez, Instituto Maimónides de Investigación Biomédica de Córdoba, Spain

Hepatitis E: diagnosis

Harry Dalton, Royal Cornwall Hospital, Truro, UK

Counselling, psychology and behaviour/lifestyle changes

David Stuart, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK

Recent data in treatment of acute hepatitis C

Christoph Boesecke, University of Bonn, Germany

Treatment as prevention: modelling data

Natasha Martin, University of Bristol, UK

Should HIV-positive patients be prioritised for hepatitis C treatment?

Sanjay Bhagani, Royal Free Hospital, London, UK
Mark Nelson, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK

Separate clinical trials for co-infected patients are a necessity

Access to hepatitis C treatment

Svilen Konov, HIV i-Base, London, UK



Registration
open at
www.bhiva.org

AUTUMN CONFERENCE PROGRAMME

FRIDAY 13 NOVEMBER 2015



BHIVA AUTUMN CONFERENCE

◀ All sessions will be held in the Fleming, Third Floor, QEII Centre unless otherwise stated ▶

| | |
|-----------|--|
| 0810–1440 | Registration and exhibition open |
| 0825–0855 | <p>BHIVA Breakfast Workshop (Abbey, Fourth Floor) Chair: Miss Michelle Croston <i>Manchester Metropolitan University</i></p> <p>Dr Laura Waters <i>Mortimer Market Centre, London</i></p> <p>How should we train HIV specialists from 2016? Dr David Asboe <i>Chelsea and Westminster Hospital, London</i></p> <p>Dr Eileen Nixon <i>Brighton and Sussex University Hospitals NHS Trust</i></p> |
| 0900–1000 | Gilead Sciences Satellite Symposium (see page 13 for further details) |
| 1000–1030 | <p>Brian Gazzard Lectureship in HIV Medicine Chair: Professor Brian Gazzard <i>Chelsea and Westminster Hospital, London</i></p> <p>The genetics of HIV in humans Professor Paul Kellam <i>Wellcome Trust Sanger Institute, Cambridge</i></p> |
| 1030–1040 | BHIVA Awards Ceremony |
| 1040–1110 | Morning coffee |
| 1110–1140 | <p>CHIVA Plenary Lecture Chair: Dr Amanda Williams <i>London North West Healthcare NHS Trust</i></p> <p>The disclosure of an HIV-infected adult to their uninfected child Ms Rebecca Brown <i>Positive Parenting and Children (PPC)</i></p> <p>Ms Angelina Namiba <i>Salamander Trust</i></p> |
| 1140–1310 | <p>BHIVA Best Practice Management Session Chairs: Dr Annemiek de Ruiter <i>St Thomas' Hospital, London</i></p> <p>Dr David Chadwick <i>James Cook University Hospital, Middlesbrough</i></p> <p>HRT – managing HIV through the menopause Dr Shema Tariq <i>Mortimer Market Centre, London</i></p> <p>Smoking cessation Dr Louise Restrick <i>The Whittington Hospital, London</i></p> <p>Osteoporosis Dr Karen Walker-Bone <i>University of Southampton</i></p> |
| 1310–1330 | BHIVA Annual General Meeting (members only) |

AUTUMN CONFERENCE PROGRAMME

FRIDAY 13 NOVEMBER 2015

- 1310–1440 Lunch and Lunchtime Workshops
- 1335–1420 **BHIVA Lunchtime Workshop 2** (Westminster, Fourth Floor)
Lunchpacks will be provided (see page 16 for further details)
- Chair: Professor Brian Angus
University of Oxford
- Treatment failure**
Dr John Evans-Jones
Countess of Chester Hospital NHS Foundation Trust
- Dr Iain Reeves
Homerton University Hospital NHS Foundation Trust, London
- 1335–1435 **Gilead Sciences Lunchtime Workshop** (Abbey, Fourth Floor) (see page 13 for further details)
- 1335–1435 **ViiV Healthcare UK Lunchtime Workshop** (Moore, Fourth Floor) (see page 13 for further details)
- 1440–1540 **BHIVA Plenary Session 3**
- Chairs: Dr Mas Chaponda
University of Liverpool
- Dr Duncan Churchill
Royal Sussex County Hospital, Brighton
- New drugs and novel strategies**
Professor Roy Gulick
Weill Cornell Medical College, New York, USA
- Hepatitis C for the HIV doctor: drugs and drug resistance**
Dr Chloe Orkin
Barts Health NHS Trust, London
- 1540–1640 **BHIVA Interactive Clinical and Ethical Conundrums**
- Chair: Dr Andrew Freedman
Cardiff University School of Medicine
- Panellist: Professor Bobbie Farsides
Brighton and Sussex Medical School
- Ethics of disclosure and the impact of being undetectable**
Dr Margaret Kingston
Central Manchester University Hospitals NHS Foundation Trust
- Dr Mary Poulton
King's College Hospital NHS Foundation Trust, London
- Clinical cases with ethical considerations**
Dr Carol Emerson
The Royal Hospitals, Belfast
- Dr Ed Wilkins
North Manchester General Hospital
- 1640–1645 **Close by the Chair of the British HIV Association**
Dr David Asboe
Chelsea and Westminster Hospital, London

CHIVA PARALLEL SESSIONS PROGRAMME

FRIDAY 13 NOVEMBER 2015



Children's HIV Association (CHIVA) Parallel Sessions

◀ Parallel sessions will be held in the Westminster, Fourth Floor, QEI Centre, unless otherwise stated ▶

Please read the **CHIVA Parallel Sessions** programme in conjunction with the **BHIVA Autumn Conference** programme

TRANSITION...MIND THE GAP

| | |
|-----------|--|
| 0810–1440 | Registration and exhibition open |
| 0850–0900 | Welcome Address by the Chair of the Children's HIV Association Dr Amanda Williams London North West Healthcare NHS Trust |
| 0900–1040 | CHIVA Parallel Session 1 Chairs: Dr Fiona Thompson <i>Northampton General Hospital NHS Trust</i> Dr Tomás Campbell <i>Consultant Clinical Psychologist, London</i> |
| 0900–0930 | Implications of the START Study findings for paediatric HIV treatment Dr Anna Turkova <i>Imperial College Healthcare NHS Trust, London</i> |
| 0930–1010 | Managing toxicity, side effects and adherence Miss Maren Koros <i>Portsmouth Hospitals NHS Trust</i> Miss Katie Rowson <i>MRC Clinical Trials Unit at UCL, London</i> |
| 1010–1040 | Social support for children under 13 who know their diagnosis: including feedback from CHIVA Summer Camp and other camps Ms Amanda Ely <i>CHIVA Projects</i> |
| 1040–1110 | Morning coffee Britten, Third Floor |
| 1110–1140 | CHIVA Plenary Lecture Fleming, Third Floor (see page 8 for further details) |
| 1150–1310 | CHIVA Parallel Session 2 Chairs: Dr Jolanta Bernatoniene <i>Bristol Royal Hospital for Children</i> Dr Velur Balasubramaniam <i>Derby Teaching Hospitals NHS Foundation Trust</i> |
| 1150–1215 | Learning from the Science Museum and NCB Participator Project Miss Emily Hamblin <i>National Children's Bureau</i> |

CHIVA PARALLEL SESSIONS PROGRAMME

FRIDAY 13 NOVEMBER 2015

- 1215–1245 **Women who decline HIV testing in pregnancy: a survey of local policy & practice**
Dr Laura Byrne
UCL Institute of Child Health, London
- 1245–1310 **What impact do children's attachment styles have on the health care relationship?**
Practical considerations for healthcare workers
Dr Tomás Campbell
Consultant Clinical Psychologist, London
- 1310–1440 **Lunch and Lunchtime Workshops**
Britten, Third Floor
- 1440–1700 **CHIVA Parallel Session 3**
Chairs: Dr Srinu Bandi
Leicester Royal Infirmary
Miss Emily Hamblin
National Children's Bureau
CHIVA Projects Update
Ms Amanda Ely
CHIVA Projects
- 1500–1700 **A multidisciplinary approach to managing transition**
- 1500–1515 **The young person's perspective**
CHIVA Youth Committee
- 1515–1530 **The teacher's perspective**
Mrs Gina Macrae
Reddish Vale High School, Stockport
- 1530–1600 **The healthcare professional's perspective**
Ms Sara Ayres
Imperial College Healthcare NHS Trust, London
Dr Sarah Fidler
Imperial College Healthcare NHS Trust, London
- 1600–1620 **The psychologist's perspective**
Dr Kathy White
Central and North West London NHS Foundation Trust
- 1620–1640 **Transition in other chronic diseases**
Dr Janet McDonagh
University of Manchester
- 1640–1700 **Panel discussion**
- 1700 **Close by the Chair of the Children's HIV Association**
Dr Amanda Williams
London North West Healthcare NHS Trust

PROGRAMME OF SATELLITE SYMPOSIA AND LUNCHTIME WORKSHOPS

All satellite symposia will be held in the Fleming, Third Floor, QEI Centre
Locations of sponsors' workshops are listed below adjacent to the respective events

THURSDAY 12 NOVEMBER 2015

0900–1000

Bristol-Myers Squibb Pharmaceuticals Satellite Symposium
Optimising current treatment strategies in HIV therapy

Chair: Dr Alan Winston
Imperial College Healthcare NHS Trust, London

Introduction: recent developments in HIV therapy

Dr Alan Winston
Imperial College Healthcare NHS Trust, London

Fine tuning ART initiation: did the DHHS guidelines get it wrong?

Dr Graeme Moyle
Chelsea and Westminster Hospital, London

The role of clinical pharmacology – past, present and future – in optimising therapy

Professor David Back
University of Liverpool

Discussion: questions and answers from the audience

Dr Alan Winston
Imperial College Healthcare NHS Trust, London

1255–1355

Janssen Lunchtime Workshop (Abbey, Fourth Floor)
Case discussion: optimising treatment using current guidelines

Dr Mas Chaponda
University of Liverpool

Dr Tristan Barber
Chelsea and Westminster Hospital, London

Dr Alison Barbour
St George's Hospital, London

1255–1355

Pfizer Lunchtime Workshop (Moore, Fourth Floor)
What's new? What you need to know now about immunisation in HIV-positive adults

Dr David Chadwick
James Cook University Hospital, Middlesbrough

Dr Mark Lawton
Liverpool Centre for Sexual Health

Dr Eithne MacMahon
Guy's and St Thomas' Hospital NHS Foundation Trust, London

1730–1830

ViiV Healthcare UK Satellite Symposium
Perspectives in practice: from science to clinic

Chair: Dr Annemiek de Ruiter
St Thomas' Hospital, London

Dr Marta Boffito
Chelsea and Westminster Hospital, London

Dr Carol Emerson
The Royal Hospitals, Belfast

Professor Anna Maria Geretti
University of Liverpool

PROGRAMME OF SATELLITE SYMPOSIA AND LUNCHTIME WORKSHOPS

All satellite symposia will be held in the **Fleming, Third Floor**, QEll Centre
Locations of additional workshops are listed below, adjacent to the respective sessions

FRIDAY 13 NOVEMBER 2015

0900–1000

Gilead Sciences Satellite Symposium

'HIV is:'

Chair: Dr Anton Pozniak
Chelsea and Westminster Hospital, London

HIV is: About women

Dr Laura Waters
Mortimer Market Centre, London

HIV is: About men

Dr Anton Pozniak
Chelsea and Westminster Hospital, London

1335–1435

Gilead Sciences Lunchtime Workshop (Abbey, Fourth Floor)

What would it take to eliminate HCV from the HIV population?

Chair: Professor Mark Nelson
Chelsea and Westminster Hospital, London

What would it take to eliminate HCV from the HIV population?

Professor Peter Vickerman
University of Bristol

Eliminating HCV in clinical practice: a case-based discussion

Professor Mark Nelson
Chelsea and Westminster Hospital, London

1335–1435

ViiV Healthcare UK Lunchtime Workshop (Moore, Fourth Floor)

'Growing up positively' care to share

Chair: Ms Angelina Namiba

Speakers:

The workshop will consist of five young adults (16–21) living with HIV in the UK. The symposium will explore what it is like to grow up with HIV in the UK today using a mixture of creative pieces and an interactive question and answer session.

BHIVA COMMITTEES

EXECUTIVE COMMITTEE

OFFICERS

Chair

Dr D Asboe Chelsea and Westminster Hospital, London

Vice Chair

Dr AJ Palfreeman Leicester Royal Infirmary

Honorary Secretary

Dr A de Ruiter St Thomas' Hospital, London

Honorary Treasurer

Dr D Churchill Royal Sussex County Hospital, Brighton

MEMBERS

Prof B Angus University of Oxford

Prof M Bower Chelsea and Westminster Hospital, London

Mr G Brough UK Community Advisory Board

Dr D Chadwick James Cook University Hospital, Middlesbrough

Dr M Chaponda Royal Liverpool University Hospital

Professor L Dorrell University of Oxford

Dr AR Freedman Cardiff University School of Medicine

Prof B Gazzard CBE Chelsea and Westminster Hospital, London

Professor C Leen Western General Hospital, Edinburgh

Ms S Morris Western General Hospital, Edinburgh

Dr C Orkin Barts Health NHS Trust, London

Prof C Sabin University College London

Dr A Sullivan Chelsea and Westminster Hospital, London

Dr M Tenant-Flowers King's College Hospital NHS Foundation Trust, London

Dr L Waters Mortimer Market Centre, London

CONFERENCES SUBCOMMITTEE

Dr C Orkin Chair and BHIVA Executive Committee member

Dr L Waters Vice Chair and BHIVA Executive Committee member

Dr D Asboe BHIVA Executive Committee member

Mr G Brough BHIVA Executive Committee member and Community Representative

Dr D Churchill BHIVA Executive Committee member

Dr M Chaponda BHIVA Executive Committee member

Dr A de Ruiter BHIVA Executive Committee member

Dr C Emerson Invited Representative

Prof B Gazzard CBE BHIVA Executive Committee member

Prof C Leen BHIVA Executive Committee member

Ms S Morris BHIVA Executive Committee member

Dr A Palfreeman BHIVA Executive Committee member

Prof C Sabin BHIVA Education and Scientific Subcommittee Chair

Dr M Tenant-Flowers BHIVA Executive Committee member and Local Host

Dr E Wilkins Invited Representative

SPONSORS AND EXHIBITORS

BHIVA MAJOR SPONSORS 2015

AbbVie Ltd

AbbVie House
Vanwall Business Park
Maidenhead
Berkshire SL6 4XE



Bristol-Myers Squibb Pharmaceuticals Ltd

Uxbridge Business Park
Sanderson Road
Middlesex UB8 1DH



Bristol-Myers Squibb

Gilead Sciences Ltd

280 High Holborn
London
WC1V 7EE



GILEAD

Janssen

50-100 Holmers Farm Way
High Wycombe
Buckinghamshire HP12 4DP



MSD Ltd

Hertford Road
Hoddesdon
Hertfordshire EN11 9BU



MSD

ViiV Healthcare UK Ltd

Stockley Park West
Uxbridge
Middlesex UB11 1BT



EXHIBITORS

Commercial

6PM & 6PM Blithe

Invitec

Positive Conversations

REACH

Community

Body and Soul

Centre for All Families Positive Health (CAFPH)

Children's HIV Association

NAM

National AIDS Trust

Positively UK

Saving Lives

Terrence Higgins Trust

The Sophie Forum

UK-CAB / HIV i-Base

BHIVA major sponsors and commercial exhibitors have supported the BHIVA Autumn Conference by purchasing exhibition stand space.



CONFERENCE INFORMATION

Registration

Your registration fee includes access to the scientific sessions as indicated below for each meeting, including satellite symposia and exhibition stands.

BHIVA Autumn Conference: 12–13 November 2015

The registration fee gives access to the scientific sessions of the BHIVA Autumn Conference and the CHIVA Parallel Sessions, including satellite symposia. All refreshments and lunches throughout the conference are included in the registration fee.

The Parallel Sessions are preceded by the CHIVA Dinner at Bank Restaurant from 2000 on Thursday 12 November for those who have booked tickets and paid the necessary fee.

BHIVA Lunchtime Workshops

Places are limited and will be restricted to 80 delegates per workshop. Places will be available on site, on a first-come-first-served basis, at the door of the lunchtime workshop. Doors will open 15 minutes prior to the start of each workshop.

Each workshop will begin promptly and lunchpacks will be provided for delegates attending these sessions.

Prizes and awards

The Don Jeffries BHIVA Research Award

BHIVA created this award in honour of the late Professor Don Jeffries. This will be awarded for the highest-scoring application, as judged by the BHIVA Research Awards Judging Panel, from the 17 applications submitted for the 2015 BHIVA Research Awards. The award will be presented in the Lecture Theatre at the BHIVA Awards Ceremony at 1030–1040 on Friday 13 November 2015.

BHIVA Best Case Presentation

A prize will be awarded to the presenter of the best Clinico-pathological case presentation.

Janssen Travel Bursary Scholarships in collaboration with BHIVA

Janssen in collaboration with the British HIV Association (BHIVA) made provision for eight scholarship awards to be made available to assist healthcare professionals to attend the International AIDS Society conference which was held in Vancouver, Canada on 19–22 July 2015. Scholarship awards were capped at a maximum of £2,000 each and were considered a contribution towards an award winner's registration fee, travel and accommodation expenses.

Drinks Reception

The Drinks Reception immediately follows the conference programme at 1830–1930 on Thursday 12 November and will take place in the exhibition area located in the Britten on the Third Floor.

Continuing Professional Development (CPD)

Medical staff in career grade posts who are enrolled with one of the Royal Medical Colleges for Continuing Professional Development will receive CPD credit at the rate of one CPD credit per conference hour (exclusive of travel, refreshments, social events and satellite symposia). The conference will be allocated a maximum of 6 CPD credits per conference day.

| CPD Accreditation: Credits attributed and unique reference number | | |
|---|------------|-------|
| BHIVA Autumn Conference including CHIVA Parallel Sessions | 12 Credits | 98788 |
| CHIVA Parallel Sessions only | 6 Credits | 98788 |

CONFERENCE INFORMATION

BHIVA Community Registration

BHIVA has supported free registrations for over 50 community representatives to attend the conference.

BHIVA Registration Scholarships

BHIVA Registration Scholarships have been made available to 10 delegates who are doctors and who are retired, not working or employed in a part-time or equivalent capacity, or who are students involved in full-time undergraduate or post-graduate work. The scholarships cover the conference registration fee.

Cloakroom

A staffed cloakroom is available at the QEII Centre. All belongings are left at the owner's risk. The QEII Centre and the British HIV Association do not accept responsibility for the loss of, or damage to, delegates' personal property stored in the cloakroom areas.

Conference venue

QEII Centre

Broad Sanctuary · Westminster · London SW1P 3EE · Tel: +44 (0)20 7222 5000 · Web: qeicc.co.uk

The conference venue is a short walk from Westminster or St James's Park underground stations.

Please see the map for the location of these stations in relation to the **QEII Centre**.

Westminster and St James's Park underground stations are easily accessible from King's Cross, St Pancras (Eurostar) and Victoria main-line rail stations and can be accessed by the Jubilee line or the Circle and District lines. The journey from these main-line stations to Westminster or St James's Park underground stations takes approximately 10 minutes.

There are also good links to the city centre from both Heathrow and Gatwick airports. Journeys by either Heathrow or Gatwick Express take about 1 hour


There are four car parks near to the conference venue. For further information please visit www.ncp.co.uk

Please note that the conference venue is located within the London Congestion Charge Zone.



EXHIBITION FLOOR PLAN AND EXHIBITORS

QEI Centre · London



EXHIBITORS

- | | |
|---|---------------------------|
| 1 Centre for All Families Positive Health (CAFPH) | 11 REACH |
| 2 Children's HIV Association (CHIVA) | 12 Invitec |
| 3 NAM | 13 Positive Conversations |
| 4 National AIDS Trust | 14 Body and Soul |
| 5 Positively UK | 15 Sophia Forum |
| 6 6PM & 6PM Blithe | 16 UK-CAB / HIV i-Base |
| 7 Saving Lives | 17 ViiV Healthcare UK Ltd |
| 8 AbbVie Ltd | 18 Janssen |
| 9 Bristol-Myers Squibb Pharmaceuticals Ltd | 19 Gilead Sciences Ltd |
| 10 MSD Ltd | 20 Terrence Higgins Trust |

PLENARY SPEAKER BIOGRAPHIES

David Asboe is Clinical Director of HIV Medicine and Sexual Health at Chelsea and Westminster Hospital, London. He has been Chair of BHIVA since 2013 and is also Convenor of the Diploma in HIV Medicine exam run by the Worshipful Society of Apothecaries.

Brian Angus is Associate Professor and Reader in Infectious Diseases in the Nuffield Department of Medicine, Oxford University, and a Senior Clinical Scientist with the MRC CTU. He is also Director of Oxford University's Centre for Tropical Medicine and Global Health and NHS Clinical Lead for ID in the Oxford University Hospitals Trust. Brian is chairing the BHIVA guidelines on routine investigation monitoring of HIV-1-infected adults writing group.

Sara Ayres is a registered general nurse (RGN), with over 15 years of nursing experience. She is a registered district nurse with a degree from King's College London and is an independent nurse prescriber. Sara has been working with adults and adolescents with HIV since 2002, providing comprehensive care both within the hospital setting and in the community. She currently works at St Mary's Hospital in the HIV Adult Clinic and as part of the multidisciplinary team within the Adolescent Clinic.

Abdel Babiker is a Scientific Programme Leader at the MRC Clinical Trials Unit and a Professor of Epidemiology and Medical Statistics at UCL. He has worked for many years on the development and implementation of clinical trials in HIV and other infections, including the SPARTAC and NEAT 001 trials. Abdel currently co-chairs the START trial, conducted by the INSIGHT network, and sits on the WHO/TDR Advisory Committee on Research in Integrated Community Case Management of Childhood Illness.

Rebecca Brown is the Deputy Director of Positive Parenting and Children. Her passion is supporting children and families. Rebecca has extensive experience working with families, children and young people living with or affected by HIV, having worked in the HIV sector for nearly 20 years. She started out at River House providing a crèche service for what was then Positively Women. She has worked at PPC for 13 years. Rebecca has a degree in social work from London South Bank University, and her interest is child protection and HIV.

Laura Byrne is an MRC Clinical Training Research Fellow working on the National Study for HIV in Pregnancy and Childhood at the UCL Institute of Child Health. She is in her last year of a PhD in Epidemiology looking at HIV in pregnancy in the UK, focusing on antiretroviral treatment, drug resistance, and eliminating mother-to-child transmission. After this, Laura will return to complete her specialist training in Genitourinary and HIV Medicine at Barts Health NHS Trust in East London.

Tomás Campbell is a Consultant Clinical Psychologist and Neuropsychologist. He is a member of CHIVA's National Executive and sits on the conference and guidelines subcommittees. He has developed transition and parenting interventions for children/families with HIV to enhance coping. Tomás is working on developing clinical guidelines for the identification and management of neuropsychological issues in children and adolescents. He also works for CHIVA Africa and supports the WhizzKids United Health Academy in KwaZulu-Natal.

Duncan Churchill has been a Consultant in GU/HIV medicine at the Royal Sussex County Hospital in Brighton since 1999. He trained at Oxford University and at the Middlesex Hospital Medical School. Before taking up his current appointment he was a Lecturer and Honorary Senior Registrar at Imperial College School of Medicine at St Mary's, and also worked as HIV Registrar at the Middlesex Hospital. Duncan was a member of the BHIVA executive committee from 1996 to 2004 and from 2009 to date, and has been on the BHIVA guidelines subcommittee since inception. He is currently Chair of the guidelines subcommittee, Honorary Treasurer of BHIVA and Chair of the BHIVA guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy writing group. Duncan's interests include antiretroviral drug therapy and toxicity and he also works in the Patient Safety Department at RSCH.

Robbie Currie has been involved in HIV for over 25 years and his experience in the sector ranges from being a volunteer at the London Lighthouse in the mid-1980s to, more recently, managing the national HIV prevention programmes for MSM (men who have sex with men) and African communities for the Department of Health. Robbie is currently Sexual Health Commissioner for the London Borough of Bexley. He has considerable experience of working with marginalised groups of people, in particular those who have experienced stigma, prejudice and discrimination, enabling them to address health inequalities through community engagement and empowerment.

Valerie Delpech is a Medical Epidemiologist based at Public Health England and leads a team of scientists and data managers to monitor the HIV epidemic and quality of care people living with HIV receive in the UK. Valerie's research interests focus on better understanding the epidemiology of HIV and STIs, and public health interventions to prevent these infections among vulnerable populations. She serves on a number of national and international committees in relation to HIV public health monitoring, prevention and policy development and is an Executive Trustee for the National AIDS Trust

PLENARY SPEAKER BIOGRAPHIES

Amanda Ely is currently CHIVA Projects Social Care Lead and Volunteer Manager for CHIVA Support Camp. She is also a Lecturer in Childhood studies for the Open University. Amanda is a qualified social worker experienced in working in the voluntary and statutory sectors, with a special focus on the psychosocial impacts of HIV. She has a special interest in the psychosocial impacts of HIV on children and families.

Carol Emerson has been a Consultant Physician in HIV/GUM at Belfast Trust since 2008. She sits on the BHIVA conferences subcommittee and is a member of the BHIVA guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy writing group. As a previous new consultant representative, Carol set up the New Consultant Forum and helped merge it with the BASHH mentoring group.

John Evans-Jones is a Consultant in Genitourinary Medicine in Chester. He has an interest in education and is currently Clinical Lead for eHIV-STI, part of Electronic Learning for Healthcare (eLFH) from Health Education England. He is also interested in research and contributes to a number of NIHR portfolio studies. John is an active member of the Merseyside, Cheshire and North Wales HIV Managed Care Network, for which he co-chairs the Perinatal HIV MDT.

Sarah Fidler works in the Department of Medicine at Imperial College London as a Reader and Consultant Physician in HIV Medicine. Her clinical work includes provision of medical care for individuals presenting with acute HIV infection. In addition she jointly leads a specialist clinic for adolescents and young people perinatally infected with HIV. Sarah has been involved in designing and leading HIV clinical studies around the role of immediate ART at the time of HIV seroconversion for the past 15 years and since 2012, she has led the development of the UK HIV Cure initiative (CHERUB). Sarah is also co-PI of an international community randomised study (HPTN071-PopART) in Zambia and South Africa testing a combination HIV prevention programme on HIV incidence.

Brian Gazzard started the HIV unit at the Chelsea and Westminster Hospital and is now its Clinical Research Director. This is one of the largest clinical units in Europe, concentrating its research mainly on new algorithms of care, immunological and oncological manifestations of HIV disease and antiretroviral therapy. Brian qualified at Cambridge University and received his MD from that institution in 1983. He was awarded the Department of Health Prize for Distinguished Achievement in 2002 and is the Chairman of the Expert Advisory Group on AIDS (EAGA).

Roy Gulick is Gladys and Roland Harriman Professor of Medicine and Chief of the Division of Infectious Diseases at Weill Medical College of Cornell University, and Attending Physician at the New York Presbyterian Hospital in New York City. His research interests include designing, conducting and analysing clinical trials to refine antiretroviral therapy strategies for HIV treatment and prevention. He is principal investigator of the Cornell Clinical Trials Unit of the NIH-funded AIDS Clinical Trials Group (ACTG). Roy also serves as the Co-chair of the US Department of Health and Human Services (DHHS) Panel on Clinical Practices for Treatment of HIV Infection, is a Member of the NIH Office of AIDS Research Advisory Committee (OARAC), a Board Member of the International Antiviral Society-USA, and previously served as a Member and as Chairman of the Antiviral Drugs Advisory Committee of the US Food and Drug Administration (FDA). Roy is a Member of the American Society of Clinical Investigation, the Association of American Physicians, International AIDS Society, and the Infectious Diseases Society of America, and has presented at national and international meetings and published widely.

Emily Hamblin is a Senior Development Officer at the National Children's Bureau, where she works on a range of health issues, on practice development, policy, research, participation, information provision and creating resources with and for young people. This has included coordinating NCB's Children and Young People HIV Network, which works with young people living with and affected by HIV as well as practitioners, decision-makers and researchers, to advocate for and improve care and support for this group. Emily has been a trustee of the Children's HIV Association of the UK and Ireland (CHIVA) since 2010.

Alastair Hudson has been working with the People Living with HIV Stigma Index since 2009 as the UK Country Coordinator. He has worked as a freelance media consultant with several HIV organisations to date, including the International Planned Parenthood Federation (IPPF), African Health Policy Network (AHPN), Brook Young People and NAZ, and is currently a trustee at Leicester AIDS Support Services (LASS).

Laura K is an expert patient who has been living with HIV for about three years. She belongs to different HIV networks including UK-CAB, Sophia Forum, Ourspace-Peterborough, Forum Link and Positively Ageing Forum. She is a peer mentor who initially went to Positively UK in search of ongoing peer support and decided to train to be a peer mentor. Laura has gone on to start and currently co-ordinates a peer-led support group in Peterborough. She is also an expert patient speaker.

PLENARY SPEAKER BIOGRAPHIES

Paul Kellam is the Viral Genomics Group Leader and Senior Investigator at the Sanger Institute and a Professor of Viral Pathogenesis at UCL. His research on HIV-1 drug resistance identified one of the essential reverse transcriptase mutations conferring resistance to zidovudine and how multiple mutations led to high-level resistance to antiviral drugs. In 2009 Paul established the Virus Genomics Laboratory at the Sanger Institute. His laboratory identified the first influenza disease severity-determining allele and has also produced the majority of the genome analysis of the Middle East respiratory syndrome coronavirus outbreaks in Saudi Arabia.

Margaret Kingston has been a GUM Consultant at Manchester Royal Infirmary (part of Central Manchester Foundation Trust, CMFT) since 2003. Together with obstetric, midwifery and neonatal colleagues she established the HIV antenatal clinics at St Mary's Hospital (also CMFT) in 2006, where many complex pregnancies in HIV-positive pregnant women are managed. Margaret has been the Chair of the BASHH National guidelines for the management of syphilis in 2008 and 2015 and a BASHH Clinical Effectiveness Group member since 2010. She is Training Programme Director for GUM in the northwest and an Associate Director of Medical Education at CMFT.

Maren Koros has worked as an HIV Pharmacist for both Adult and Paediatric Services at the Portsmouth Hospitals NHS Trust. Her role has been to ensure safe, effective, efficient evidence-based use of medication. Maren is a member of the UK Children's HIV Association (CHIVA) guidelines committee and has been involved in the review and writing of local, prevention of vertical transmission guidelines as well as the international guidelines on the treatment of HIV in the paediatric population. She is also a volunteer for CHIVA-South Africa and takes part in the mentoring of pharmacists and nurses in South Africa.

Sebastian Lucas has spent three decades as a histopathologist, studying the clinical pathology of HIV/AIDS in UK and Africa. His main concerns have been making best use of biopsy and autopsy material to further diagnostics, better patient management, and in research.

Janet McDonagh is a Clinical Senior Lecturer in Paediatric and Adolescent Rheumatology at the Centre for Musculoskeletal Research at the University of Manchester and Honorary Consultant Paediatric and Adolescent Rheumatologist at Royal Manchester Children's Hospital. Originally trained in adult rheumatology, she moved into paediatric rheumatology where she has since developed her clinical and research interests in adolescent health and transitional care. Janet has a particular interest in models of care for adolescents with chronic conditions that support young people's emerging capacity for self-management, that ensure appropriate health risk assessment, support transition to adult healthcare, adherence to treatment and engagement with other healthcare services. She is a member of the Barbara Ansell National Network for Adolescent Rheumatology, convenor of the Royal College of Paediatrics and Child Health Young Person's Special Interest Group and is Co-chair of the Royal College of Physicians Young Adult and Adolescent Strategy Group. Janet is also involved in the development of training for health professionals in adolescent medicine including her role as a trainer in the European Teaching Effective Adolescent Care and Health initiative.

Aoife Molloy is a Specialty Registrar in Acute Medicine and Infectious Diseases. She is a member of the BHIVA audit subcommittee and worked on the National audit of monitoring of adults with HIV. She was a National Medical Director's Clinical Fellow at the National Institute for Health and Care Excellence (NICE) in 2014 and 2015 and is currently working on a quality strategy report on the NHS at the Health Foundation. Aoife is passionate about person-centred care and patient safety, leadership and healthcare professional decision-making skills.

Angelina Namiba has over 16 years' experience of working in the HIV sector on initiatives ranging from providing one-to-one support to people living with HIV, managing service provision to facilitating, promoting and advocating for the involvement of women living with HIV in forming and informing local and national strategy and policy. She also works with adolescents and young people living with HIV, where she supports them around various issues and coping strategies including HIV treatment literacy and general well-being around living with HIV. Angelina is passionate about advocating for the sexual health and reproductive rights of women living with HIV. From 2012 to 2015 she managed the project From Pregnancy to Baby and Beyond, which provided information, emotional and practical peer support to pregnant women living with HIV, men living with HIV and their sero-different partners. One of her greatest hopes for the future is for the day when treatment for HIV will be available, affordable and accessible to all those who need it globally.

Anthony Nardone is a Consultant Scientist in Public Health England with a responsibility for HIV Prevention and Sexual Health Promotion programme within PHE. He has over 20 years' experience as an infectious disease epidemiologist and has worked in a number of countries and different disease areas and has published extensively in international peer-reviewed scientific journals. Anthony has a major interest in HIV prevention and the monitoring and evaluation of public health programmes.

PLENARY SPEAKER BIOGRAPHIES

Eileen Nixon has been a Nurse Consultant in HIV since 2004. She has served on the NHVNA executive committee and was co-author of the National HIV Nursing Competencies. She represented NHVNA members on the HIV Clinical Reference Group from April 2013 to January 2015. Eileen's current clinical practice focuses on engagement in care and complex case management and she has been involved in setting up HIV nurse education courses in the UK and developing county settings. Her main research interests are around HIV service delivery and she has recently completed post-doctoral research on HIV and co-morbid conditions to inform future service models.

Chloe Orkin is Consultant and Honorary Reader in HIV Medicine at the Royal London Hospital and runs an HIV and HIV/hepatitis C research unit. She has 70 peer-reviewed publications and has been a writing group member on four BHIVA guidelines. Chloe is External Examiner to the Diploma in HIV Medicine. She is researching ways of implementing HIV and blood-borne virus testing.

Mags Portman is a Consultant in Sexual Health and HIV at Mortimer Market Centre, London. She completed training in sexual health in Leeds and has also worked in sexual health in York, Glasgow and East London. She actively involved in the PROUD study at Barts Health. Her interests include HIV testing and prevention and HIV in women.

Mary Poulton has been a Consultant in Genitourinary Medicine since 2001 and was Clinical Lead for Sexual Health and HIV at King's College Hospital before taking up a Divisional Clinical Director role there. Her interests include management of HIV in pregnancy and medical ethics, particularly confidentiality and issues pertaining to prosecutions for sexual transmission of HIV. Mary previously spent four years as a Caldicott Guardian during which time she completed a Masters in Medical Ethics and Law at Keele University. Other relevant ethics experience includes: Chair of BASHH Information Group 2008–2012 and Chair of the writing group for the 2013 BHIVA position statement 'HIV transmission, the law and the work of the clinical team'.

Michael Rayment is a Consultant in Sexual Health and HIV Medicine at Chelsea and Westminster Hospital NHS Foundation Trust, and an Honorary Senior Clinical Lecturer at Imperial College London. He has a career-long research interest in HIV testing, investigating the effectiveness and sustainability of testing strategies to reduce undiagnosed HIV infection.

Iain Reeves is Clinical Lead for HIV at the Homerton University Hospital. He co-chairs the network-level treatment advice clinic and is principal investigator on a number of HIV research trials.

Louise Restrict works as an inner-city Consultant Respiratory Physician at Whittington Health and in Islington, where 1-in-5 people die from tobacco smoking. She is committed to delivering high 'value' care (best outcomes/lowest cost) and hence to collaborative working in identifying and treating tobacco dependence. Louise co-leads the London Respiratory Network and is a member of the London Senate sponsored 'Helping Smokers Quit' programme.

Katie Rowson has been involved with the care of children and young people living with HIV through the last decade with a number of years' experience working as a Paediatric Nurse Specialist coordinating the care of children and young people living with HIV. Katie currently works as a Research Nurse at the MRC Clinical Trials Unit at UCL on the AALPHI Study and as a Lecturer in Children's Nursing at the University of Central Lancashire. For the past couple of years she has regularly taken part in the CHIVA-Africa programme. Katie has volunteered at CHIVA camp since it started in 2010 and is a member of the CHIVA executive committee.

Alex Sparrowhawk recently joined Terrence Higgins Trust as their Membership and Involvement Officer. Prior to his appointment he had volunteered for the organisation's myHIV service as an Online Peer Support Volunteer. Keen to utilise his own experiences and understanding of HIV, Alex also provides face-to-face peer support with George House Trust as part of their being+ project for gay men in employment or under 30 in Manchester. Alex is open about his HIV status believing that HIV-positive people should be visible role models in their communities in order to fight the stigma they face.

Shema Tariq is a Postdoctoral Clinical Research Fellow at UCL's Centre for Sexual Health & HIV Research and Honorary Consultant at Mortimer Market Centre. Her main area of interest is the reproductive and post-reproductive health of women living with HIV. Shema's academic experience includes doctoral research exploring HIV-positive African migrant women's engagement with HIV care in the UK during pregnancy, and a Fulbright Scholarship to Columbia University to analyse cohort data on late HIV diagnosis in KwaZulu-Natal. Shema is currently Chief Investigator of the PRIME Study, an NIHR-funded study investigating the impact of the menopause on HIV-positive women's health and well-being.

PLENARY SPEAKER BIOGRAPHIES

Melinda Tenant-Flowers is a Consultant in HIV/Sexual Health at King's College Hospital, London. Her research interests include HIV oncology and HIV testing. Melinda is a writing group member of both the 2014 BHIVA guidelines on HIV-associated malignancy and the current BHIVA guidelines on routine investigation and monitoring of HIV-1-infected adults, is lead for BHIVA E-Learning CPD, is a member of the BHIVA education/scientific and conferences subcommittees and is an examiner for the Diploma in HIV Medicine.

Marc Thompson has been living with HIV since 1986 and has worked in the HIV and sexual health sector for over 20 years. He is currently the National Coordinator of Project 100 at Positively UK, which aims to provide peer mentoring and support to people living with HIV across the UK. Before joining Positively UK, Marc worked in a range of local and national organisations including THT, GMFA, Big Up and Living Well, developing interventions to improve sexual health, reduce stigma and improve the wellbeing of PWHIV. His interest in the intersection of ethnicity, sexuality and HIV and the impact it has on individuals and society drives Marc's commitment to social justice and informs his work.

Anna Turkova is a Paediatrician at Imperial College Healthcare Trust, London and a Research Clinician at the MRC CTU at UCL and the Paediatric European Network for Treatment of AIDS (PENTA). She is coordinating PENTA research and training activities in Eastern Europe with focus on HIV, TB and viral hepatitis. Anna was a lecturer on PENTA training courses 2011–2015. Prior to coming to the UK in 2002, she worked for four years in Paediatric Infectious Diseases in Russia. She has been a CHIVA executive committee member since 2015; a member of European Society of Paediatric Infectious Diseases (ESPID) and the Paediatric Tuberculosis Network European Trials group (pTbNet). Anna's special interests are HIV, co-infections, viral hepatitis and TB.

Karen Walker-Bone trained as an academic rheumatologist with a special interest in osteoporosis and metabolic bone diseases in Southampton. Between 2003 and 2013, Karen became Senior Lecturer in Rheumatology and Clinical Academic Sub-Dean at the new Brighton and Sussex Medical School where she played a significant role in developing and delivering the curriculum to the first cohorts of medical students. It was here that Karen started a rheumatology HIV service. In 2013, she returned to the MRC Lifecourse Epidemiology Unit in Southampton as Associate Professor in Rheumatology, and here has started a new clinic in Southampton for HIV-infected patients with rheumatic diseases.

Laura Waters is a GU/HIV Consultant at the Mortimer Market Centre, London, working predominantly in HIV and hepatitis Outpatients; she is Hepatitis Lead and HIV Inpatient Lead. Prior to her current appointment in 2012 she worked in clinical trials at Chelsea & Westminster and Brighton, completing an MD on antiretroviral simplification and switch. Laura has published and presented widely on topics including drug toxicity and contraception for HIV-positive women, is Vice Chair of the BHIVA guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy writing group and Chair of the BASHH HIV Special Interest Group.

Kathy White is a Clinical Psychologist, and currently works within three multidisciplinary teams: Mortimer Market's HIV and Sexual Health Service for adults, Margaret Pyke Centre's Sexual Problems Assessment and Treatment Service (SPATS), and Mortimer Market's clinic for adolescents and young people who are living with HIV (TEAM clinic). She is the only psychologist within TEAM clinic, and appreciates working with a multidisciplinary approach when supporting young people. Kathy is passionate about ensuring young people are offered genuinely holistic care, in ways which are meaningful and accessible to them.

Ed Wilkins is a Consultant in Infectious Diseases and Co-director of the HIV Research Unit at North Manchester General Hospital. Prior to taking up his current position, he trained in Infectious Diseases in London and Liverpool, Tropical Medicine in Africa, and Medical Microbiology with the Health Protection Agency. He has been involved with HIV patient care and research since 1984 with interests in antiretroviral toxicity and hepatitis co-infection. He is heavily involved in clinical trials as well as many executive and advisory national committees including BHIVA.

Ian Williams is a Senior Lecturer in the Research Department of Infection and Population Health at University College London and an Honorary Consultant Physician at Central North West London NHS Trust and University College London Hospitals NHS Trust. He has extensive clinical and research experience in HIV medicine. Ian was BHIVA Chair from 2008 to 2011 and has been a panel member of several national and international clinical guideline committees including Chair of the BHIVA guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy writing group in 2012. Ian has been a member of the NHS England Clinical Reference Group for HIV since 2013 and is the current Chair.

For the treatment of HIV, choose a

DOLUTEGRAVIR-BASED REGIMEN


One core agent. Many different patients.



Simplicity of dolutegravir
in a single-pill regimen



Flexibility to build a
tailored treatment regimen



www.dolutegravir.com

TRIUMEQ is indicated for the treatment of HIV-infected adults and adolescents above 12 years of age weighing at least 40 kg.

Before initiating treatment with abacavir-containing products, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. Abacavir should not be used in patients known to carry the HLA-B*5701 allele.

TIVICAY is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-infected adults and adolescents above 12 years of age.

Prescribing Information

Triumeq ▼ dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg tablets

See Summary of Product Characteristics before prescribing.

Indication: HIV in over 12 years and ≥ 40 kg. Screen for HLA-B*5701 prior to use. Do not use if HLA-B*5701 positive. **Dose:** one tablet once daily with or without food. **Elderly:** Limited data in 65+ yrs. **Creatinine clearance** < 50 ml/min or moderate/severe hepatic impairment: Not recommended. **Contraindications:** Hypersensitivity to any ingredient. Co-administration with dofetilide. **Warnings/precautions:** Both abacavir and dolutegravir are associated with risk of hypersensitivity reactions (HSR). Do not initiate in HLA-B*5701+ or previous suspected abacavir HSR. Stop Triumeq without delay if HSR suspected. Never reintroduce any dolutegravir- or abacavir-containing product after suspected HSR. Risks of lactic acidosis, lipodystrophy, immune reactivation syndrome, osteonecrosis. Monitor LFTs in Hepatitis B/C co-infection. Inconclusive data on relationship between abacavir and MI; minimise all modifiable CV risk factors (e.g. smoking, hypertension, hyperlipidaemia). Not recommended if dolutegravir required b.d. (with etravirine (without boosted PI), efavirenz, nevirapine, rifampicin, boosted tipranavir, carbamazepine, oxcarbazepine, phenytoin, phenobarbital and St John's Wort). Use with cladribine not recommended. Use with Mg/Al-containing antacids, calcium, multivitamins or iron requires dosage separation. Caution with metformin: monitor renal function and consider metformin dose adjustment. Caution with ribavirin. **Pregnancy/lactation:** Not recommended. Avoid breast-feeding. **Side effects:** See SPC for details. Headache, insomnia, sleep/dream disorders, GI disturbance, fatigue, hypersensitivity, anorexia, depression, dizziness, somnolence, lethargy, malaise, cough, nasal symptoms, rash, pruritus, alopecia, arthralgia, muscle disorders, asthenia, fever, elevations of ALT, AST and CPK, blood dyscrasias, suicidal ideation or suicide attempt, rhabdomyolysis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis. **Basic NHS costs:** 30 tablets: £798.16 EU/1/14/940/001. MA holder: Viiv Healthcare UK Ltd, 980 Great West Road, Brentford, Middlesex TW8 9GS. Further information is available from Customer Contact Centre, GlaxoSmithKline UK Ltd, Stockley Park West, Uxbridge, Middlesex UB11 1BT.

POM

Triumeq is a registered trademark of the Viiv Healthcare Group of Companies

Date of approval: July 2015

Zinc code: UK/TRIM/0037/14(3)

Adverse events should be reported. For the UK, reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

Adverse events should be reported. For Ireland, adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971, medsafety@hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Tivicay ▼ dolutegravir 50 mg tablets Prescribing Information

See Summary of Product Characteristics before prescribing

Indication: HIV in > 12 years and ≥ 40 kg as part of combination therapy. **Dosing:** 50 mg once daily with or without food if no proven/suspected integrase resistance. 50 mg twice daily with efavirenz, nevirapine, tipranavir/ritonavir, etravirine (without boosted PI), carbamazepine, oxcarbazepine, phenytoin, phenobarbital, St John's Wort or rifampicin. **Adults with proven/suspected integrase resistance:** 50 mg twice daily preferably with food. **Elderly:** Limited data in 65+ yrs. Caution in severe hepatic impairment. **Contraindications:** Hypersensitivity to any ingredient. Co-administration with dofetilide. **Warnings/precautions:** Risk of hypersensitivity reactions. Discontinue dolutegravir and other suspect agents immediately if suspected. Risks of osteonecrosis, immune reactivation syndrome. Monitor LFTs in Hepatitis B/C co-infection and ensure effective Hepatitis B therapy. Caution with metformin: monitor renal function and consider metformin dose adjustment. Use with etravirine requires boosted PI or increased dose of dolutegravir. Use with Mg/Al-containing antacids, calcium, multivitamins or iron requires dosage separation. **Pregnancy/lactation:** Not recommended. Avoid breast-feeding. **Side effects:** See SPC for full details. Headache, GI disturbance, insomnia, abnormal dreams, depression, dizziness, rash, pruritus, fatigue, elevations of ALT, AST and CPK, hypersensitivity, suicidal ideation or suicide attempt. **Basic NHS costs:** 30 tablets \$498.75 EU/1/13/892/001. MA holder: Viiv Healthcare UK Ltd, 980 Great West Road, Brentford, Middlesex TW8 9GS. Further information available from Customer Contact Centre, GlaxoSmithKline UK Ltd, Stockley Park West, Uxbridge, Middlesex UB11 1BT.

POM

Tivicay is a registered trademark of the Viiv Healthcare Group of Companies

Date of approval: August 2015

Zinc code: UK/DLG/0055/13(7)



TRIUMEQ and TIVICAY are registered trademarks of the Viiv Healthcare group of companies.
©2015 Viiv Healthcare group of companies All rights reserved.

UK/HIV/0060/15 Date of preparation: July 2015